Thrombopoiesis-Stimulating Agents (TPO)

The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development.
The product portfolio and R&D pipeline includes six products on the market, further eight clinical stage and further ten preclinical new molecules in various indications from the product categories antibody, protein, peptide and small molecule (NCE). Thrombopoiesis stimulating agents are under evaluation for treatment of idiopathic thrombocytopenic purpura (ITP) and for prevention of severe thrombocytopenia induced by chemotherapy.

The report includes a compilation of marketed products and current active projects in research and development of molecules targeting the TPO, IL-11 or other receptors. In addition, the report lists company-specific product portfolio and R&D pipelines of thrombopoiesis stimulating agents. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.